CompletedNCT00537901Updated Dec 17, 2015

First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study

An interventional study of First-Line Bevacizumab and Chemotherapy and Bevacizumab in Colonic Neoplasms and Rectal Neoplasms, sponsored by King Faisal Specialist Hospital & Research Center. Completed. Per ClinicalTrials.gov, last updated 2015-12-17.

Sponsored by King Faisal Specialist Hospital & Research Center · Not applicable, Interventional, and Treatment

Phase: Not applicable
Study type: Interventional
Enrollment: 100
Allocation: Non-randomized
Sex: All

Study summary

First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum

Conditions studied

Colonic Neoplasms
Rectal Neoplasms

Browse trials for

Keywords

Colon and Rectum Cancer

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 100 is above the median of 50 across 7,253 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

King Faisal Specialist Hospital & Research Center is the lead sponsor of 98 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible: All
Accepts healthy volunteers: No

Eligibility criteria

Inclusion Criteria:

Patients with metastatic cancer of colon or rectum

Study design

Phase: Not applicable
Primary purpose: Treatment
Allocation: Non-randomized
Intervention model: Single group
Masking: None (open label)
Enrollment: 100 participants (actual)

Interventions

RadiationFirst-Line Bevacizumab and Chemotherapy
Chemotherapy
DrugBevacizumab
Chemotherapy

What researchers measure

Primary outcomes

Effectiveness
Time frame: overall

Secondary outcomes

Quality of life
Time frame: overall

Study locations

No study locations are listed for this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Dec 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT00537901
Lead sponsor: King Faisal Specialist Hospital & Research Center
Responsible party: Dr. Naeem A. Chaudhri (Principal Investigator, King Faisal Specialist Hospital & Research Center) — Principal investigator
First posted: Oct 2, 2007
Start date: Oct 2007
Primary completion: Oct 2013
Completion: Oct 2013
Last update: Dec 17, 2015

Study contacts

Shouki Bazarbashi, MD

principal investigator · KFSH & RC

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms→

Other studies from this sponsor

King Faisal Specialist Hospital & Research Center

Start the discussion